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Aim To evaluate the influence of oxidative stress on extra-
pituitary growth hormone (GH) secretion in the eye and to 
analyze the interdependence between eye and serum GH 
levels under normal and hypoxic conditions.
Methods Pars plana vitrectomy (PPV) was performed in 
32 patients with developed proliferative diabetic retinop-
athy (PDR) and 49 non-diabetic controls, both of whom 
required this procedure as part of their regular treatment 
in the period from April 2013 to December 2014. During 
PPV, vitreous samples were taken and blood was simulta-
neously collected from the cubital vein. GH levels in serum 
and vitreous samples were measured by electrochemical 
luminescence assay. Oxidative stress was measured by en-
zyme-linked immunosorbent assay of advanced oxidation 
protein products (AOPP) and lipid hydroperoxide (LPO) in 
serum and vitreous.
Results Serum AOPP levels were significantly higher than 
vitreous levels in both groups (P < 0.001 for each group) 
and LPO levels were significantly higher only in PDR 
group (P < 0.001). There was a significant positive correla-
tion between serum and vitreous LPO levels in PDR group 
(r = 0.909; P < 0.001). Serum GH levels were significantly 
higher than vitreous levels in both groups (P < 0.001 for 
each group). Serum GH levels were significantly higher in 
PDR group than in controls (P = 0.012). Vitreous GH values 
were slightly higher in PDR group, but the difference was 
not significant.
Conclusion Our study confirms that GH production in the 
eye is autonomous and independent of oxidative stress or 
pituitary GH influence.
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The latest research has indicated that the secretion of 
growth hormone (GH) in human retinal ganglion cells 
(RGC) is maintained throughout the postembryonic life, 
and has a neuroprotective role (1-8). Serum human GH 
levels are elevated in diabetes and their possible correla-
tion with etiopathogenesis of diabetic retinopathy (DR) 
has been investigated, but not confirmed (9-12). Diabetes 
is considered to be a primarily metabolic disorder that, 
besides leading to other complications, affects small and 
large blood vessels, thus causing hypoxia and oxidative 
stress in different tissues and organs. Therefore, DR rep-
resents an ideal model for exploring extrapituitary GH re-
lease, as well as various aspects of serum GH production 
(13). However, we still do not know the exact mechanism 
of how serum human GH interferes with the develop-
ment of DR. The key assumption is that reduced amounts 
of insulin in the portal circulation reduce insulin growth 
factor 1 (IGF1) production in the liver with the final lack 
of feedback inhibition of increased GH secretion (12,13). 
All this takes place in conditions of hyperglycemia that is 
being suppressed by introduction of additional amounts 
of insulin, which provides the necessary condition for in-
creased portal IGF1 production. In this stage of the dis-
ease, circulating values of both GH and IGF1 are elevated 
in serum (11,13,14) and this stage is usually associated 
with the appearance of DR. It has been proven that IGF1 
exerts a promotional effect on neovascularization and 
proliferative changes in the eye, but it is unclear whether 
the increased levels of IGF1 measured in diabetic vitreous 
are derived from the passage of serum IGF1 through the 
blood retinal barrier (BRB) or it is autonomous growth fac-
tor created within the eye (15,16).
There are controversial findings on the effects of iatrogen-
ic GH medical suppression in serum on DR. Some earlier 
studies, primarily on animal models, have shown that sup-
pression of serum GH decreases the synthesis of IGF1 and 
thus slows down DR progression (17,18). Recent studies on 
a large number of human participants have shown that 
suppression of serum GH, despite the accompanying re-
duction in serum IGF1 levels, does not affect the stage of 
DR, which implies the existence of an autonomous IGF1 
production in the eye (16,19).
It should be noted that insulin is significant IGF 1 secretion 
promoter just like GH, and that patients with type I and 
some with type II diabetes receive insulin therapy as their 
standard treatment procedure. Nevertheless, in such con-
ditions insulin increasingly penetrates the BRB and addi-
tionally stimulates autonomous creation of IGF1 in the eye 
(20-23). In normal conditions, this barrier is impermeable 
to GH and IGF1, but animal model studies showed that in 
conditions of hypoxia and oxidative stress it became per-
meable to both molecules (13,21,24). Human model, how-
ever, showed that the GH concentration in vitreous was 
lower in diabetic than in nondiabetic patients. This fact 
rules out the possibility of excessive serum GH passing 
through the damaged BRB, but indicates autonomous pro-
duction of GH within the eye (13,25). It is believed that so-
matostatin (SST), also known as inhibitor of GH secretion, 
is an important regulator of GH homeostasis in the eye and 
its production is confirmed in the retinal ganglion cells and 
retinal pigment epithelial cells (RPE) cells (26,27).
The aim of this study was to explore GH secretion and its 
dependence on oxidative stress in the eye and also its cor-
relation with GH in the systemic circulation. We assumed 
that the eye production of GH in oxidative stress was re-
duced due to the simultaneous apoptosis of neural cells 
that produce it.
Patients, MateRial, and Methods
This case-control study was conducted at the Zagreb Uni-
versity Clinical Hospital “Sveti Duh,” Opthmalmology De-
partment, Zagreb, Croatia in the period from April 2013 
to December 2014. Eligible were patients with previously 
diagnosed proliferative diabetic retinopathy (PDR) associ-
ated with type II diabetes mellitus who underwent clas-
sic three port pars plana vitrectomy (PPV). Non-inclusion 
criteria were positive history of intraocular bleeding or in-
flammation, history of vitreoretinal surgery or retinal pho-
tocoagulation, history of intravitreal steroid or anti-VEGF 
therapy, current systemic steroid or cytostatic therapy, 
poorly controlled cardiovascular status, and pregnancy. 32 
patients were enrolled. Type II diabetes mellitus was de-
fined according to the World Health Organization criteria, 
and PDR according to the Early Treatment Diabetic Retin-
opathy Study criteria. Control group consisted of 49 non-
diabetic patients who underwent PPV in the same period 
for causes other than PDR with no signs of neovsculariza-
tions, inflammation, or vascular obstruction. The groups 
were age and sex matched.
The study was approved by the Ethics Committee of the 
Clinical Hospital “Sveti Duh”, Zagreb and was conducted at 
the Ophthalmology Clinic, University Hospital “Sveti Duh”, 
Zagreb, in accordance with all applicable guidelines: Ba-
sics of Good Clinical Practice, the Helsinki Declaration, 
and the Croatian Healthcare Act and Patients’ Rights 
CLINICAL SCIENCE328 Croat Med J. 2015;56:326-33
www.cmj.hr
Act. All patients gave written informed consent to partici-
pate in the study.
Vitreous and blood sampling
Undiluted vitreous samples (1.0-1.5 mL) were collected at 
the inception of vitrectomy by aspiration without cutting 
into a 1 mL syringe attached to the vitreous cutter (Ultravit 
cutter, Constellation Vision System, Alcon, Johns Creek, GA, 
USA). The vitreous was obtained under the air infusion be-
fore starting intravitreal infusion of a balanced salt solution. 
Immediately after collection, samples were transferred to 
a sterile tube with coverlid (Eppendorf, Hamburg, Germa-
ny) and taken to the laboratory. Samples were centrifuged 
at 15 000 g for 10 min at 4°C and separated supernatants 
were frozen at -80°C until final assessment. Venous blood 
samples were collected simultaneously and centrifuged 
at 3500 g for 10 min at 4°C, after which separated serums 
were frozen at -80°C until they were assayed. In vitreous 
and serum samples, two oxidative stress parameters, ad-
vanced oxidation protein products (AOPP) and lipid per-
oxidation (LPO), and GH levels were measured. In oxidative 
stress, major degradation changes occur in cell protein and 
lipid structures. Therefore, AOPP and LPO were selected for 
this study among common laboratory tests broadly used 
for oxidative stress evaluation over last decade.
aoPP assay
AOPP was assayed with the OxiSelect AOPP ELISA assay 
kit (Cell Biolabs, Inc., San Diego, CA, USA) according to 
the manufacturer’s instructions. AOPP content was deter-
mined by comparing the tested sample with the chloram-
ine standard curve. Briefly, 200 μL of samples or standards 
was added to separate wells of the microtiter plate (BIO-
RAD, Hercules, CA, USA). A total of 10 μL of Chloramine Re-
action Initiator (part of OxiSelect AOPP ELISA kit) was add-
ed. The absorbance of each well was recorded immediately 
on a spectrophotometric plate reader using a wavelength 
of 340 nm MRX (Dynex Technologies GmbH, Denkendorf, 
Germany). Results were calculated according to standard 
curve and expressed as µM.
lPo assay
LPO was assayed with Lipid Hydroperoxide ELISA assay kit 
(Cayman Chemical Company, Ann Arbor, MI, USA) by direct 
measurement of redox reaction with iron ions according 
to the kit manual. Briefly, in 500 µL test samples, the so-
lution “LPO Assay Extract R” (part of OxiSelect AOPP 
ELISA assay kit) was added. To this mixture, 1 mL of cold 
chloroform solution was added, blended, and centrifuged. 
A total of 450 µL of mixture chloroform-methanol was add-
ed to 500 µL of extract chloroform-sample, followed by a 50 
µL mixture of chromogen, which turned purple. The absor-
bance was measured at 500 nm with a Spectro UVD-3500 
spectrophotometer (Labomed Inc, Los Angeles, CA, USA). 
From the calibration curve of LPO, we calculated the con-
centration of LPO in each sample according to the formula 
specified by the manufacturer and expressed as µM.
Gh assay
GH levels were measured by electrochemical lumines-
cence assay using the analyzer Cobas e411 (Roche Diag-
nostics GmbH, Mannheim, Germany). In the first incuba-
tion, sandwich formation of GH samples, byotin labeled 
monoclonal antibody, and ruthenium labeled specific 
polyclonal antibody for GH was created. After second in-
cubation with streptavidin, newly formed complex was 
magnetically bound to electrode surface. Chemical lumi-
nescence triggered with controlled voltage and emitted 
by ruthenium complex was measured with photomultipli-
cational analyzer. GH levels were calculated from the cali-
bration curve. All the reagents and the calibrator were ob-
tained from the same manufacturer like the analyzer.
statistical analysis
Continuous variables are presented as mean ± standard 
deviation, or as median and range if the distribution was 
not normal. Normality was assessed using the Kolmogo-
rov-Smirnov test. Categorical variables are presented as 
percentages. Between group analyses of categorical vari-
ables were performed using the t test for normally distrib-
uted data and Mann-Whitney test for non-normally distrib-
uted data. χ2 test was used for comparison of categorical 
data. Correlation was estimated by either the Spearman or 
Pearson coefficient. All tests were two-tailed and P < 0.05 
was considered statistically signficant. All analyses were 
performed using Statistica software package v 12 (StatSoft, 
Inc., Tulsa, OK, USA, 2014).
Results
There were no significant differences in sex between 
control group and PDR group (P = 0.829). However, con-
trol group was significantly older than PDR group (mean 
age ± standard deviation, 69.4 ± 11.6 years vs 61.3 ± 12.2 
years; P = 0.001).
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AOPP levels were significantly higher in serum than in vit-
reous, both in PDR group (median and range, 348.0 [102.0-
1358.0] µM vs 30.50 [6.0-453.0] µM, P < 0.001) and con-
trol group (248.0 [94.0-362.0] µM vs 30.0 [1.0-195.0] µM, 
P < 0.001) (Figure 1A). PDR group had significantly higher 
serum AOPP levels than control group (P = 0.005), whereas 
vitreous AOPP levels did not differ significantly between 
the groups (P = 0.179).
LPO levels were significantly higher in serum than in vitreous 
in PDR group (169.0 [78.0- 214.0] µM vs 150.5 [89.0-201.0] 
µM, P < 0.001), but not in control group (25.0 [12.0-68.0] µM 
in serum and 24.0 [9.0-78.0] µM in vitreous, P = 0.413). PDR 
group had significantly higher levels than controls in both 
serum and vitreous (P < 0.001 in both cases) (Figure 1B). 
Positive correlation between LPO levels in serum and vitre-
ous was detected in both groups. This correlation was not 
significant in control group (r = 0.228; P = 0.115), but was 
significant in PDR group (r = 0.909; P < 0.001). This signifi-
cant correlation in PDR group was tested for causality us-
ing simple linear regression method resulting in high value 
outcome with R˛ value of 0.780 (P < 0.001) (Figure 2).
GH concentrations were significantly higher in serum than 
in vitreous both in PDR group (866.4 [45.7-8702.0] pg/mL vs 
51.3 [20.80-162.7] pg/mL, P < 0.001) and control group (492.4 
[83.3-3190.0] pg/mL vs 34.0 [20.2-172.4] pg/mL, P < 0.001) 
(Figure 1-C). Serum GH levels were significantly higher in 
PDR than in control group (P = 0.012), while the levels did 
not differ significantly in vitreous (P = 0.439). Similarly to LPO 
levels, correlation between GH levels in serum and vitreous 
was significant in PDR group (r = 0.691; P < 0.001), but not in 
control group (r = 0.084; P = 0.567). This significant correla-
tion in PDR group was tested for causality using simple lin-
ear regression method resulting in high value outcome with 
R˛ of 0.527 (P < 0.001) (Figure 2). We correlated GH levels with 
FiGuRe 1. levels for advanced oxidation protein products (aoPP) (A), lipid peroxidation (lPo) (B), and growth hormone (Gh) (C) as 
median (square), interquartile range (box), non-outlier range (whiskers), outliers (circles), and extremes (asterisks). levels in serum 
are shown as white boxes and vitreous levels are shaded in gray. C – control group; PdR – proliferative diabetic retinopathy group.
FiGuRe 2. Regression graphs for lipid peroxidation (lPo) levels in serum and vitreous (A) and growth hormone levels in serum and 
vitreous (B). C – control group; PdR – proliferative diabetic retinopathy group.
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AOPP and LPO in serum and vitreous separately, but none of 
these correlations was significant.
disCussion
By measuring the concentration of GH and parameters of 
oxidative stress in serum and vitreous we showed that GH in 
the eye was independent of serum GH. We also noticed that 
GH production was not reduced and thus not directly de-
pendent on oxidative stress in the eye of diabetic patients.
Association between GH and DR is well known (9-12,28-
30). For decades it was thought that the pituitary GH is one 
of the main promoters of DR development. However, this 
role has recently been attributed to IGF1 (15,31). Different 
medications or surgical and radiological methods were 
used to influence GH-IGF1 axis with the aim to suppress 
pituitary gland or circulating growth factors (32-36).
Recent literature indicates that GH is also produced in the 
eye. The initial investigation was performed on a chicken 
embryo model, followed by a rat model, and research us-
ing bovine model is under way (1,4,37,38). It has been prov-
en that eye GH secretion exists in embryonic life of differ-
ent animal species even before the start of pituitary gland 
activity and that its role is important in eye embryogenesis 
(2,3). In vertebrates and especially mammals, postnatal eye 
GH activity and its neuroprotective role in postembryonic 
life have been confirmed (7,8). When suppressed, neuronal 
deterioration of the optic nerve and some neuronal layers 
of the retina have been reported (7,8,39,40). These findings 
have opened new questions about the interaction of GH 
and DR occurrence.
GH was found in samples of RGC cultures, thus confirm-
ing that it is the product of those specific cells and its se-
cretion is assumed to be autonomous and independent of 
the pituitary (7). Such assumption is based on the fact that 
the GH secretion in the eye does not decrease with age 
like in serum and that diabetic patients have lower levels of 
vitreous GH than non-diabetic participants because of as-
sumed RGC death due to PDR (15,41-43). This is supported 
by a previous study (31), which also reported reduced vit-
reous level of IGF1 in diabetic patients since production of 
IGF1 is GH-dependent. We wanted to investigate the direct 
relationship between serum and vitreous GH in order to ac-
complish comparative conclusions. Therefore, we directly 
compared serum and vitreous samples from the same 
patients. We used a human model of DR, as was done in 
previous research (15,16). PDR is a convenient model 
since it meets two relevant requirements. One is the link 
between GH and the etiology of DR (10-12) and the oth-
er is hypoxia and neural cell death (13,21,25). Our results 
showed that there were no significant difference between 
the total GH concentration in diabetics’ and controls’ vitre-
ous. These results are contrary to our expectations based 
on published data on lower GH levels in diabetic vitreous, 
which was explained by RGC apoptosis (31,41). It should 
be noted that our control group had an identical pattern 
of ocular pathology to that shown in other studies (7,41). 
However, there are also studies reporting elevated levels of 
vitreous GH and IGF1 in diabetics (16,44).
Due to the penetration of proteins through the BRB in PDR 
some authors have additionally corrected vitreous GH con-
centration for the amount of total protein composition in 
the vitreous since autonomous GH is free and the rest is 
bind to the proteins, which made the levels of vitreous 
GH even lower in absolute terms (15,31,41). Almost iden-
tical concentrations of GH in the vitreous of diabetics and 
controls in our study confirmed independent-secretion of 
GH in the eye, although the serum GH levels in PDR group 
were 3-fold higher than the serum levels in control group. 
This observation also suggests that the BRB, even when it 
is disrupted like in PDR, actually remains impenetrable for 
the GH molecule of 22 kDa and thus prevents serum GH 
to penetrate the eye (45,46). This particular conclusion is 
in contrast to some observations in animal models, sug-
gesting that disruption of BRB in diabetics allows the pas-
sage of molecules up to 70 kDa (24). Since previous studies 
(15,41) showed decreased levels of GH in diabetic vitreous, 
explaining them by ruination of RGC layer, equal levels of 
vitreous GH found in this study remain to be explained.
We assumed that because of the lack of production of in-
traocular SST in diabetic patients, which is also confirmed 
in the recent literature, local inhibition of GH is reduced or 
diminished (47,48). In these patients this should lead to a 
significant increase in vitreous GH levels, however it does 
not happen in such an extent, probably due to RGC apop-
tosis. Finally this leads to roughly equal vitreous GH lev-
els in controls and diabetics, as shown by our results. We 
assumed that another reason why its level of production 
remains preserved, despite the decline of ganglion cells, 
which are the main source of GH, is probably the existence 
of another GH secretion source in the eye. As a matter of 
fact, positive findings of GH immunoreactivity were found 
in the cells of the iris, ciliary, retinal pigment epithelium, 
lens, cornea, and choroid but this possibly related facts 
have not been investigated yet (49).
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We wanted first to examine quantitative parameters of oxi-
dative stress and then correlate them with GH production 
to evaluate whether, despite RGC apoptosis, production 
of GH in the eye can be retained. In diabetics, we found 
a significant correlation between serum and vitreous for 
the parameters of oxidative stress and GH, however corre-
lation between oxidative stress and GH production in the 
eye was not significant. This led us to believe that, in spite 
of neural cell apoptosis under oxidative stress, GH secre-
tion remains functional, and this fact may confirm the ex-
istence of sufficient compensatory GH secretion in other 
locations of the eye and not only in neural tissues.
Our assumption of non-neural GH secretion in the eye is 
supported by Ziaei et al (41), who found that the concen-
tration of GH in the vitreous of patients with nonprolifera-
tive DR was lower than in patients with proliferative DR. This 
finding hardly fits the hypothesis that RGC is a major and 
relevant factor of GH secretion in the eye, especially in con-
ditions of compromised homeostasis and ganglional cell 
death. Extraneural locations of GH secretion in the eye can 
obviously compensate to a certain level for a lack of primary 
neuronal production, which occurs due to neurodegenera-
tion in DR. Moreover, there are certain indicators that sug-
gest that GH may be expressed in any cell (50). An indirect 
confirmation of the sustained activity of GH is a multiple in-
crease in VEGF in the eye with DR which is a proven fact, and 
VEGF synthesis requires GH dependent IGF1 (44,47,51).
The question raised in recent years is whether diabetic 
retinopathy occurs in the exact sequence proposed by the 
classical basics of biomedical sciences. Vascular changes 
have long been regarded as the initial change and promi-
nent feature of DR. New research, however, shows that, sev-
eral years before the appearance of visible vascular chang-
es, processes like excitotoxicity and neurodegeneration are 
initiated, in which GH produced within the eye plays an 
important role (47). By comparing the same parameters in 
serum and vitreous samples, which has not been done so 
far, this study showed the independence of GH secretion 
in the eye. It also showed that the production of GH in the 
eye is not dependent on oxidative stress in DR, most likely 
due to altered homeostasis of other growth factors and ac-
tivation of non-neural GH secretion sources inside the eye. 
We explained some new details of GH behavior in DR and 
thus contributed to the understanding of new aspects in 
the development of DR.
Because of the difficulty of collecting large number of vitre-
ous samples, this study is somewhat inferior to the animal 
studies, but the number of samples tested is very similar to 
other published human studies (15,31,41,51). It is very dif-
ficult to achieve perfect match between the experimental 
and control groups, but data analysis was still performed as 
projected in the basic study design.
Further research on the role of hormonal activity of the eye 
in DR could contribute to the formation of new therapeu-
tic modalities. In particular, it would be interesting to exam-
ine the qualitative aspect of GH that is created in oxidative 
stress, because according to some indications immature 
growth factors isoforms can be neurodegenerative, and 
even mature forms may be ineffective or have altered ac-
tivity due to the hormone receptor modified expression or 
malfunction (44). Finally, emergence and speed of DR pro-
gression varies on an individual basis depending on the 
DR phenotype (47), which makes further research in this 
field even more complex. When it comes to therapy, today 
we already have broad application of VEGF molecules an-
tagonists since their angiogenic role is very pronounced in 
the course of DR. Similarly, on the basis of new knowledge 
about the importance of the role of GH, development of 
new therapeutic options is possible, particularly local ap-
plication of SST agonists or growth hormone antagonists.
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